Janssen Biotech Inc.
Horsham, PA Doing business as Centocor Ortho Biotech Inc.
- UEI
- NVYMGFA53MN7
- CAGE
- 0MJM1
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- Hopewell Township, NJ H5BMHLMMNA28
- Janssen Products, LP · Horsham, PA Z1TQMKVX5MD4
-
- SAM.gov registration date
- Physical address
- 800 Ridgeview Drive, Horsham, PA 19044, USA
- Website
- jnj.com
- Founded
- 1886
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $829,037 |
| FY2025 | -$58,653 |
| FY2024 | $986,879 |
| FY2023 | $302,748 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $829,037 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Bristol-Myers Squibb Company | Lawrence Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Insmed Incorporated | Bridgewater, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Otsuka America Pharmaceutical Inc. | Rockville, MD | 325412 Pharmaceutical Preparation Manufacturing |
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Urogen Pharma Inc. | Princeton, NJ | 325414 Biological Product (except Diagnostic) Manufacturing |
About the company
Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is a for-profit pharmaceutical manufacturer and Johnson & Johnson subsidiary that supplies specialty oncology biologic medications to the Department of Veterans Affairs as a prime contractor under full-and-open (non-set-aside) procurement, holding a $6.888 billion Federal Supply Schedule contract and a $15 million Blanket Purchase Agreement that serve as the dominant vehicles for its federal work.
Janssen Biotech's federal footprint is narrowly focused on oncology pharmaceutical supply to the VA. The company manufactures and delivers three named specialty cancer drugs—BALVERSA (erdafitinib), CARVYKTI, and WELIREG (belzutifan)—through firm fixed-price delivery orders and BPA calls issued by regional Veterans Integrated Service Networks. Representative work includes a $384,718.69 emergency pharmacy delivery order from Veterans Integrated Service Network 19 (September 3, 2026) for CARVYKTI under the Pharmaceuticals and Drugs FSS-61-IB schedule; a $20,500.10 BPA call from VISN 5 (July 31, 2026) for BALVERSA 4 MG; and a $55,140.61 delivery order from VISN 20 (June 17, 2022) for erdafitinib. Delivery orders typically range from $11,300 to $384,700 and carry thirty-day completion windows. The company holds no subcontract footprint; all 110 awards in the source data are primes.
Customer concentration is extreme. The Department of Veterans Affairs accounts for 100 percent of awards by agency. Within VA, five regional VISNs and the National Acquisition Center dominate by order count and value share. VISN 5 leads by frequency with 37 awards totaling $615 thousand, and VISN 20 follows with 11 awards totaling $530 thousand. However, dollars are anchored by VISN 12, which carries four awards with $10.36 billion combined potential value—a concentration driven by two massive IDV ceilings: the $6.888 billion Federal Supply Schedule contract awarded September 1, 2024 (expiring August 31, 2029) and the $15 million Blanket Purchase Agreement awarded September 20, 2024 (expiring September 19, 2027). Both vehicles operate under the same FSS-61-IB schedule and serve as call vehicles for rapid fulfillment across VISNs nationwide.
All 88 delivery orders and BPA calls in the source are placed against the Pharmaceuticals and Drugs (FSS-61-IB) schedule. The two parent IDVs—the Federal Supply Schedule contract and the companion single-award BPA for BALVERSA and CARVYKTI—are the operational levers for Janssen Biotech's entire VA business. Recent activity is decelerating: the vendor received 22 awards in 2024, 7 in 2025, and 4 in 2026 year-to-date, suggesting tapering call volume against the IDVs rather than new opportunity. Only one award faces ultimate completion within the next twenty-four months (a $385 thousand delivery order), creating minimal recompete risk in the near term; the two large IDV ceilings do not expire until August 2029 and September 2027 respectively.
Janssen Biotech operates through two named subsidiaries: Janssen Products LP and Actelion Pharmaceuticals US, Inc., both for-profit manufacturers. The corporate structure reflects Johnson & Johnson's diversified pharmaceutical and biologic portfolio, though the federal footprint centers exclusively on VA oncology supply. The vendor competes on open (non-set-aside) terms; its large-manufacturer status and Johnson & Johnson ownership preclude participation in 8(a), HUBZone, SDVOSB, or other federal small-business set-asides. Janssen Biotech's federal contracting posture is transactional and volume-driven: steady call orders against pre-established price lists under GSA schedules, with no prime teaming or subcontract relationships in the source data.
Quick answers
Is Janssen Biotech Inc. registered in SAM.gov?
Yes. Janssen Biotech Inc.'s SAM.gov registration is active through November 21, 2026.
Which contract vehicles does Janssen Biotech Inc. hold?
Janssen Biotech Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Janssen Biotech Inc. received in federal contracts?
Federal contracts obligated $2,060,010 to Janssen Biotech Inc. in fiscal years 2023 through 2027.
How does Janssen Biotech Inc. rank among federal contractors?
Janssen Biotech Inc. ranked #46 in PSC Q517, #58 in NAICS 325412 and #91 in NAICS 3254 in FY2025.
What is Janssen Biotech Inc.'s most recent federal award?
Janssen Biotech Inc.'s most recent federal contract award is Emergency pharmacy carvykti for RMR (36C25926F0310), from Veterans Integrated Service Network 19 (VHA), on September 3, 2026.
On GovTribe
See Janssen Biotech Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors